AR025719A1 - Metodo para tratamiento por monitoreo con una hormona paratiroidea - Google Patents
Metodo para tratamiento por monitoreo con una hormona paratiroideaInfo
- Publication number
- AR025719A1 AR025719A1 ARP000104919A ARP000104919A AR025719A1 AR 025719 A1 AR025719 A1 AR 025719A1 AR P000104919 A ARP000104919 A AR P000104919A AR P000104919 A ARP000104919 A AR P000104919A AR 025719 A1 AR025719 A1 AR 025719A1
- Authority
- AR
- Argentina
- Prior art keywords
- bone
- markers
- bone formation
- parathyroid hormone
- resorption
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- 239000005556 hormone Substances 0.000 title abstract 2
- 229940088597 hormone Drugs 0.000 title abstract 2
- 238000012544 monitoring process Methods 0.000 title abstract 2
- 230000011164 ossification Effects 0.000 abstract 5
- 210000000988 bone and bone Anatomy 0.000 abstract 4
- 102000003982 Parathyroid hormone Human genes 0.000 abstract 3
- 108090000445 Parathyroid hormone Proteins 0.000 abstract 3
- 239000000199 parathyroid hormone Substances 0.000 abstract 3
- 229960001319 parathyroid hormone Drugs 0.000 abstract 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 abstract 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 abstract 2
- 108010050808 Procollagen Proteins 0.000 abstract 2
- 230000024279 bone resorption Effects 0.000 abstract 2
- 210000004899 c-terminal region Anatomy 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 abstract 1
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 229930003316 Vitamin D Natural products 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000003150 biochemical marker Substances 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000036570 collagen biosynthesis Effects 0.000 abstract 1
- 230000011382 collagen catabolic process Effects 0.000 abstract 1
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 abstract 1
- 239000007857 degradation product Substances 0.000 abstract 1
- 102000058004 human PTH Human genes 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 230000001582 osteoblastic effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- 235000019166 vitamin D Nutrition 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 abstract 1
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 1
- 229940046008 vitamin d Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invencion se refiere a un método para monitorear los efectos de la administracion de una hormona paratiroidea mediante la correlacion con losniveles de uno o más marcadores de una actividad de esta hormona. Específicamente el presentemét odo monitorea la respuesta de un nivel de uno o más marcadoresde formacion y resorcion osea y/o un cambio temprano en el tratamiento y/o a intervalos durante y/o después del tratamiento. Los marcadores apropiados paraformacion osea incluyen unao má s enzimas indicativas de procesos osteoblásticos de formacion osea, preferiblemente fosfatasa alcalina específica de huesosy/o uno o más productos de biosíntesis de colágeno, preferiblemente un propéptido C-terminal de procolágeno I. Losmarcadores a propiados de resorcion yrecambio oseo incluyen uno o más productos de degradacion de colágeno, preferiblemente un telopéptido N-terminal (NTX). En una realizacion preferida elpresente método monitorea la respuesta de niveles demarcadores de formaci on y resorcion osea que incluyen una fosfatasa alcalina específica de huesos, unpropéptido C-terminal de procolágeno I, un N-telopéptido, o una combinacion de los mismos. También se describen métodos para el uso del cambio deun marcadorbioquímico de formacion osea para pronosticar el subsiguiente cambio de densidad mineral osea espinal resultante de la administracion repetida de una hormonaparatiroidea a un sujeto humano. Además, se describen también métodos parareducir recurrentemente el ries go tanto de fractura osea vertebral como no vertebralen un sujeto humano masculino que está en riesgo o que sufre osteoporosis. En particular, dicho método comprende administrar al sujeto masculino unahormonaparatiroidea que consiste en la secuencia 1-34 de aminoácido de la hormona paratiroidea humana sin administracion concurrente de un agente antiresorciondistinto de vitamina D o calcio, en una dosis diaria de por lo menos aproximadamente 15microgramos hasta aproximadamente 40 microgramos du rante por lo menosaproximadamente 12 meses hasta aproximadamente 3 anos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15487999P | 1999-09-20 | 1999-09-20 | |
| US15680399P | 1999-09-30 | 1999-09-30 | |
| US19637000P | 2000-04-12 | 2000-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR025719A1 true AR025719A1 (es) | 2002-12-11 |
Family
ID=27387653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000104919A AR025719A1 (es) | 1999-09-20 | 2000-09-20 | Metodo para tratamiento por monitoreo con una hormona paratiroidea |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050255537A1 (es) |
| EP (1) | EP1222465A1 (es) |
| AR (1) | AR025719A1 (es) |
| AU (1) | AU7362900A (es) |
| CA (1) | CA2387693A1 (es) |
| PE (1) | PE20010663A1 (es) |
| WO (1) | WO2001022093A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040033950A1 (en) | 2000-09-26 | 2004-02-19 | Hock Janet M. | Method of increasing bone toughness and stiffness and reducing fractures |
| JP2005525312A (ja) | 2002-01-10 | 2005-08-25 | オステオトロフィン エルエルシー | 骨同化物質を用いた骨疾患の治療方法 |
| US8088734B2 (en) | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
| AU2005244734A1 (en) | 2004-05-13 | 2005-12-01 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents |
| CA2628945A1 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| US20070226012A1 (en) * | 2005-12-13 | 2007-09-27 | Naryx Pharma, Inc. | Methods of measuring symptoms of chronic rhinosinusitis |
| EP2225559B8 (en) | 2007-12-28 | 2016-12-21 | F. Hoffmann-La Roche AG | Assessment of physiological conditions |
| JP2013512688A (ja) | 2009-12-07 | 2013-04-18 | ミシガン テクノロジカル ユニバーシティ | クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法 |
| EP3027225B1 (en) * | 2013-07-31 | 2021-03-24 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using transforming growth factor alpha |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW303299B (es) * | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
| US20040043971A1 (en) * | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
| US5945412A (en) * | 1996-12-09 | 1999-08-31 | Merck & Co., Inc. | Methods and compositions for preventing and treating bone loss |
| AR033639A1 (es) * | 1998-08-19 | 2004-01-07 | Lilly Co Eli | Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis |
| US20040033950A1 (en) * | 2000-09-26 | 2004-02-19 | Hock Janet M. | Method of increasing bone toughness and stiffness and reducing fractures |
| AU7363000A (en) * | 1999-09-20 | 2001-04-24 | Eli Lilly And Company | Method for reducing the risk of cancer |
-
2000
- 2000-09-11 AU AU73629/00A patent/AU7362900A/en not_active Abandoned
- 2000-09-11 EP EP00961713A patent/EP1222465A1/en not_active Withdrawn
- 2000-09-11 CA CA002387693A patent/CA2387693A1/en not_active Abandoned
- 2000-09-11 WO PCT/US2000/024745 patent/WO2001022093A1/en not_active Application Discontinuation
- 2000-09-20 PE PE2000000979A patent/PE20010663A1/es not_active Application Discontinuation
- 2000-09-20 AR ARP000104919A patent/AR025719A1/es unknown
-
2005
- 2005-06-14 US US11/151,907 patent/US20050255537A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1222465A1 (en) | 2002-07-17 |
| US20050255537A1 (en) | 2005-11-17 |
| WO2001022093A1 (en) | 2001-03-29 |
| PE20010663A1 (es) | 2001-06-25 |
| AU7362900A (en) | 2001-04-24 |
| CA2387693A1 (en) | 2001-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2190244T3 (es) | Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales. | |
| Dempster et al. | Anabolic actions of parathyroid hormone on bone | |
| Lane et al. | A review of anabolic therapies for osteoporosis | |
| MX9207349A (es) | Metodos para el tratamiento de osteoporosis utilizando bisfosfonatos y hormona de paratiroides. | |
| ES2163442T3 (es) | Utilizacion de particulas de una sal de calcio biocompatible y bio-reabsorbible como ingrediente activo en la preparacion de un medicamento destinado para el tratamiento local de enfermedades desmineralizantes de los huesos. | |
| CO4810383A1 (es) | Sal tartrato de un dipeptido sustituido | |
| ATE255367T1 (de) | Marknagelsystem zur frakturheilung bzw. knochenverlängerung | |
| Ma et al. | Human parathyroid hormone‐(1–38) restores cancellous bone to the immobilized, osteopenic proximal tibial metaphysis in rats | |
| BR9808786A (pt) | Composto peptìdio cìclico ou um seu sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, processos para tratar doenças associadas com a regulagem do cálcio em um paciente e para tratar a osteopenia ou a osteoporose em um mamìfero hospedeiro | |
| DE3851776D1 (de) | Verwendung von IGF-II zur Behandlung von Knochenkrankheiten. | |
| AR025719A1 (es) | Metodo para tratamiento por monitoreo con una hormona paratiroidea | |
| ATE295734T1 (de) | Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums | |
| ES2138067T3 (es) | Proceso para el tratamiento de un implante quirurgico. | |
| HUP0004560A2 (hu) | Törést gyógyító PTHrP analógok | |
| AR005987A1 (es) | Terapia combinada para la osteoporosis | |
| Patel | Current and potential future drug treatments for osteoporosis. | |
| BR9912409A (pt) | Processos de vacinação de uma ave doméstica, deredução de contaminação microbiana de avesdomésticas e de distribuição de uma proteìna emuma ave doméstica | |
| McClung | Prevention and management of osteoporosis | |
| MX9204303A (es) | Factor regulador del crecimiento de osteoclasto. | |
| Kawalkar | A comprehensive review on osteoporosis | |
| Pérez-Castrillón et al. | Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women | |
| Lau et al. | Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia | |
| NO994395L (no) | Stabilt, fast preparat som inneholder vitamin D3 og trikalsiumfosfat | |
| Vondracek et al. | Current approaches to the management of osteoporosis in men | |
| HU9301726D0 (en) | Compounds and preparatives hindering resorption of bones |